Terms: = Skin cancer AND ATF1, TREB36, 466, ENSG00000123268, P18846 AND Treatment
26 results:
1. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
[TBL] [Abstract] [Full Text] [Related]
2. Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
Gu L; Peng C; Zhang F; Fang C; Guo G
Orphanet J Rare Dis; 2021 Jun; 16(1):277. PubMed ID: 34127034
[TBL] [Abstract] [Full Text] [Related]
3. EIGHTEEN-MONTH RESULTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON VISION AND MICROCIRCULATION IN RADIATION MACULOPATHY.
Eandi CM; Polito MS; Schalenbourg A; Zografos L
Retina; 2021 Sep; 41(9):1883-1891. PubMed ID: 33411473
[TBL] [Abstract] [Full Text] [Related]
4. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Iijima K; Nishimura K; Fujii K; Hatayama T; Aoyama J; Deprince K; Lopez-Gitlitz A; McCarthy S; Larsen JS; Li J; Chi KN
Int J Urol; 2021 Mar; 28(3):280-287. PubMed ID: 33295007
[TBL] [Abstract] [Full Text] [Related]
5. Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Donati M; Zelano G; Coppola R; Cinelli E; Verri M; Persichetti P; Perrella E; Devirgiliis V; Calvieri S; Crescenzi A; Panasiti V
Ital J Dermatol Venerol; 2021 Oct; 156(5):593-598. PubMed ID: 31804055
[TBL] [Abstract] [Full Text] [Related]
6. Are the Fitzpatrick skin Phototypes Valid for cancer Risk Assessment in a Racially and Ethnically Diverse Sample of Women?
Sommers MS; Fargo JD; Regueira Y; Brown KM; Beacham BL; Perfetti AR; Everett JS; Margolis DJ
Ethn Dis; 2019; 29(3):505-512. PubMed ID: 31367171
[TBL] [Abstract] [Full Text] [Related]
7. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.
Fujimura T; Hidaka T; Kambayashi Y; Aiba S
Expert Opin Investig Drugs; 2019 Feb; 28(2):143-148. PubMed ID: 30556435
[TBL] [Abstract] [Full Text] [Related]
8. ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway.
Huang X; Yu P; Liu M; Deng Y; Dong Y; Liu Q; Zhang J; Wu T
Int Immunopharmacol; 2019 Jan; 66():236-241. PubMed ID: 30481683
[TBL] [Abstract] [Full Text] [Related]
9. Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma.
Allanson BM; Weber MA; Jackett LA; Chan C; Lau L; Ziegler DS; Warby M; Mayoh C; Cowley MJ; Tucker KM; Long GV; Maher A; Anazodo A; Scolyer RA
Pathology; 2018 Oct; 50(6):648-653. PubMed ID: 30177220
[TBL] [Abstract] [Full Text] [Related]
10. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract] [Full Text] [Related]
11. Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age.
Moyakine AV; Spillekom-van Koulil S; van der Vleuten CJM
J Am Acad Dermatol; 2017 Jul; 77(1):105-108. PubMed ID: 28190620
[TBL] [Abstract] [Full Text] [Related]
12. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract] [Full Text] [Related]
13. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.
Outani H; Tanaka T; Wakamatsu T; Imura Y; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2014 Jun; 14():455. PubMed ID: 24946937
[TBL] [Abstract] [Full Text] [Related]
14. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma.
Yang L; Chen Y; Cui T; Knösel T; Zhang Q; Geier C; Katenkamp D; Petersen I
Hum Pathol; 2012 Sep; 43(9):1463-70. PubMed ID: 22406360
[TBL] [Abstract] [Full Text] [Related]
15. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract] [Full Text] [Related]
16. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group.
Coindre JM; Hostein I; Terrier P; Bouvier-Labit C; Collin F; Michels JJ; Trassard M; Marques B; Ranchere D; Guillou L
Cancer; 2006 Sep; 107(5):1055-64. PubMed ID: 16878328
[TBL] [Abstract] [Full Text] [Related]
17. Metastatic melanoma to lymph nodes in patients with unknown primary sites.
Cormier JN; Xing Y; Feng L; Huang X; Davidson L; Gershenwald JE; Lee JE; Mansfield PF; Ross MI
Cancer; 2006 May; 106(9):2012-20. PubMed ID: 16568458
[TBL] [Abstract] [Full Text] [Related]
18. Regulation of gene expression in melanoma: new approaches for treatment.
Leslie MC; Bar-Eli M
J Cell Biochem; 2005 Jan; 94(1):25-38. PubMed ID: 15523674
[TBL] [Abstract] [Full Text] [Related]
19. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling.
Segal NH; Pavlidis P; Noble WS; Antonescu CR; Viale A; Wesley UV; Busam K; Gallardo H; DeSantis D; Brennan MF; Cordon-Cardo C; Wolchok JD; Houghton AN
J Clin Oncol; 2003 May; 21(9):1775-81. PubMed ID: 12721254
[TBL] [Abstract] [Full Text] [Related]
20. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.
Meier F; Will S; Ellwanger U; Schlagenhauff B; Schittek B; Rassner G; Garbe C
Br J Dermatol; 2002 Jul; 147(1):62-70. PubMed ID: 12100186
[TBL] [Abstract] [Full Text] [Related]
[Next]
